We currently have two portfolio companies each advancing specific assets in various stages of development that address significant unmet needs:
Giovel Pharmaceuticals is a Gastroenterology specialty portfolio company developing a novel, first-in-class therapy for functional GI disease with specific focus on Postprandial Distress Syndrome (PDS), an area of high unmet need in Gastroenterology.
Giathera Pharmaceuticals is a Gastroenterology specialty portfolio company initially focused on unmet needs in pediatrics.